by Mike Thurogood, MCIM | Apr 17, 2025 | Press Releases
17 April 2025 – Boston, MA & Staffordshire, UK – Following the FDA’s recent announcement expanding flexibility in preclinical submission evidence, Instem is reaffirming its role as the industry’s trusted provider of an end-to-end preclinical platform –...
by Mike Thurogood, MCIM | Mar 27, 2025 | Meet the Experts
Artificial Intelligence is rapidly reshaping industries across the globe — and life sciences is no exception. As the pace of innovation accelerates, the potential for AI to enhance drug discovery, streamline study management, and transform regulatory submissions is...
by Mike Thurogood, MCIM | Mar 11, 2025 | Regulatory Submission, SEND
The pharmaceutical industry is constantly looking for ways to streamline drug development while maintaining rigorous safety and regulatory standards. One of the most significant advancements in this effort is the International Council for Harmonisation (ICH) S1B(R1)...
by Mike Thurogood, MCIM | Jan 8, 2025 | Press Releases, Provantis, Study Management
Streamlining Pathology Workflows with Modern, Integrated Tools Stone, Staffordshire, UK — January 8, 2025 — Instem, a global leader in IT solutions for life sciences, has announced the launch of its new Non-GLP Pathology Module for Provantis, the market share-leading...
by Mike Thurogood, MCIM | Dec 23, 2024 | Press Releases
Instem is excited to announce that as of today it has closed on an acquisition of Trimetra. This acquisition aligns with our strategic vision of growth through organic and inorganic channels. Trimetra is a software development and consultancy business based in...
